Details for Patent: 10,945,950
✉ Email this page to a colleague
Which drugs does patent 10,945,950 protect, and when does it expire?
Patent 10,945,950 protects OHTUVAYRE and is included in one NDA.
This patent has sixty-two patent family members in twenty-eight countries.
Summary for Patent: 10,945,950
| Title: | Liquid inhalation formulation comprising RPL554 |
| Abstract: | The present invention relates to a liquid pharmaceutical composition suitable for administration by inhalation which comprises a diluent and a suspension of particles of 9,10-dimethoxy-2-(2,4,6-trimethylphenylimino)-3-(N-carbamoyl-2-aminoethyl)-3,4,6,7-tetrahydro-2H-pyrimido[6,1-a]isoquinolin-4-one (RPL554) or a pharmaceutically acceptable salt thereof. Also described is a liquid pharmaceutical composition according to the invention for use in the treatment of the human or animal body. |
| Inventor(s): | Spargo Peter Lionel, French Edward James, Haywood Phillip A. |
| Assignee: | VERONA PHARMA PLC |
| Application Number: | US15927517 |
|
Patent Claim Types: see list of patent claims |
Recent additions to Drugs Protected by US Patent 10,945,950
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Type | RLD | Patent No. | Product | Substance | Delist Req. | Patent Expiration | Usecode | Patented / Exclusive Use |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Verona Pharma | OHTUVAYRE | ensifentrine | SUSPENSION | 217389 | Jun 26, 2024 | RX | Yes | ⤷ Sign Up | Y | ⤷ Sign Up | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Type | >RLD | >Patent No. | >Product | >Substance | >Delist Req. | >Patent Expiration | >Usecode | >Patented / Exclusive Use |
Drugs Protected by US Patent 10,945,950
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Verona Pharma | OHTUVAYRE | ensifentrine | SUSPENSION;INHALATION | 217389-001 | Jun 26, 2024 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 10,945,950
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| Australia | 2015316592 | ⤷ Sign Up | |||
| Australia | 2018286571 | ⤷ Sign Up | |||
| Australia | 2020203081 | ⤷ Sign Up | |||
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
